AOD-9604 Research

What is AOD-9604?

AOD-9604 (Aod-9604) is a synthetic peptide consisting of 15 amino acids—specifically the C-terminal fragment (amino acids 176–191) of human growth hormone. This fragment was engineered to retain the lipolytic (fat-burning) properties of hGH while eliminating its anabolic and growth-promoting effects, particularly IGF-1 stimulation. The modification makes it theoretically safer for research and reduces metabolic side effects associated with full-length hGH.

AOD-9604 is classified as a research chemical and is not approved by the FDA for human use. It operates through distinct mechanisms than other weight-loss peptides, making it a unique subject in metabolic research.

The Monash University Development Program

AOD-9604 originated from research at Monash University in Australia beginning in the mid-1990s. Researchers sought to isolate the fat-loss properties of hGH while avoiding its growth-promoting and IGF-1 effects. The hypothesis was elegant: if they could extract just the lipolytic fragment, they could achieve targeted fat reduction without systemic growth hormone side effects.

The peptide was synthesized and initially tested in animal models, where it demonstrated promising results in reducing fat mass and improving body composition. These early successes prompted further development and clinical progression toward human trials.

Phase 2 Clinical Trial Evidence

AOD-9604 advanced to Phase 2 human clinical trials, where researchers evaluated safety, tolerability, and preliminary efficacy. The trial enrolled over 900 obese participants across multiple sites. Key findings included:

• Weight reduction: Participants receiving AOD-9604 showed modest but measurable fat loss compared to placebo, with reductions ranging 1–4kg over 12–24 weeks depending on dosage.
• Minimal side effects: The peptide was well-tolerated with adverse events similar to placebo (headache, mild injection-site reactions).
• No hGH-related complications: Critical findings showed AOD-9604 did NOT elevate IGF-1 levels, did not increase blood glucose, and did not show the diabetogenic effects associated with full hGH.
• Body composition shifts: Some trials reported modest improvements in lean mass retention, suggesting preferential fat loss.

These Phase 2 results were encouraging but not revolutionary—AOD-9604 showed promise but required longer-term studies and larger efficacy trials to justify progression to Phase 3.

Metabol and Commercial Development History

AOD-9604 was developed and commercialized by the Australian company Metabol. The company pursued regulatory approval from the Therapeutic Goods Administration (TGA), Australia's equivalent to the FDA. Metabol conducted the Phase 2 trials and planned Phase 3 efficacy studies to support a full regulatory submission.

However, in 2007, Metabol discontinued development of AOD-9604, citing financial and strategic reasons rather than safety concerns. This halt occurred before Phase 3 completion, leaving the clinical evidence base incomplete. Without Phase 3 data, regulatory agencies worldwide remained reluctant to approve it for medical use.

Following Metabol's withdrawal, AOD-9604 entered the research chemical and supplement market where it remains today—available for research purposes but unregulated and unapproved for prescription use.

Current Evidence: What We Know

Supported by Research:

• AOD-9604 stimulates lipolysis (fat breakdown) at the cellular level in animal models.
• It inhibits lipogenesis (fat storage) in isolated adipose tissue.
• Does not elevate IGF-1 in human subjects across Phase 2 trials.
• No significant impact on blood glucose or insulin sensitivity in trial participants.
• Well-tolerated with low adverse event rates in tested populations.

Evidence Gaps:

• No completed Phase 3 trials—efficacy data is limited to Phase 2.
• Long-term safety (beyond 24 weeks) is unknown.
• No human studies on high-dose protocols or extended cycling.
• Limited data on interaction with other peptides or supplements.
• No comparative studies versus modern weight-loss medications (e.g., GLP-1 agonists).
• No long-term follow-up on participants from the original trials.

Mechanism of Action: Why AOD-9604 Works (Theoretically)

AOD-9604 binds to hGH receptors on fat cells (adipocytes), triggering a cascade that increases lipolysis. The mechanism differs from other peptides:

Direct Lipolysis

When AOD-9604 binds to hGH receptors, it activates hormone-sensitive lipase (HSL), an enzyme responsible for breaking down triglycerides into free fatty acids and glycerol. This process accelerates fat mobilization, especially in abdominal and visceral adipose tissue.

Suppression of Fat Storage

Simultaneously, AOD-9604 inhibits lipoprotein lipase (LPL), an enzyme that facilitates fat uptake and storage in adipocytes. By reducing LPL activity, the peptide makes it harder for fat to accumulate in cells even when calories are abundant.

No Systemic Growth Effects

Unlike full-length hGH, AOD-9604 does not trigger insulin-like growth factor 1 (IGF-1) production in the liver or activate growth signaling pathways. This selective targeting is what theoretically makes it "safer"—you get fat loss without growth effects.

Comparison to Other Weight-Loss Peptides

Why Development Was Discontinued

Metabol's decision to halt AOD-9604 development in 2007 was surprising given the Phase 2 results were favorable. The most likely reasons:

• Cost: Phase 3 trials are expensive (tens of millions of dollars). Modest weight-loss efficacy (1–4kg) may not have justified investment.
• Market timing: Metabol may have faced financial constraints unrelated to the science itself.
• Regulatory hurdles: Approval timelines were unpredictable, and competitors were entering the peptide space.
• Patent considerations: The patent on AOD-9604 was set to expire, reducing commercial incentive.

No safety crisis triggered the discontinuation—this is important to note. Metabol didn't stop because AOD-9604 caused adverse events; they stopped for business reasons.

Modern Research Gaps and Unanswered Questions

Since 2007, AOD-9604 research has largely moved to the underground peptide community. Academic interest has been limited, and no new human trials have been published. Key unanswered questions include:

• Does AOD-9604 work better at higher doses (>1,000 mcg/day) than those tested in Phase 2?
• What is the optimal cycle duration? (Phase 2 used 12–24 weeks; longer cycles are untested.)
• Are there organ-specific effects on liver or kidney function with extended use?
• Does it interact negatively with other peptides (e.g., CJC-1295, BPC-157)?
• What happens to weight loss after stopping AOD-9604? Is fat rebound common?

Bottom Line: Research Status in 2026

AOD-9604 remains an interesting but incomplete research story. The evidence base is limited to Phase 2 trials from 15+ years ago, showing modest fat loss and good tolerability. Development was discontinued for financial reasons, not safety concerns. Today, the peptide exists in a regulatory gray zone—available for research but unapproved, with no new human data to inform modern protocols.

For researchers considering AOD-9604, the honest assessment is: it may work, but the supporting evidence is outdated and incomplete. More robust comparative studies against modern alternatives would be necessary to definitively establish its place in metabolic research.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

FAQ: AOD-9604 Research